Company Profile
Revelation Biosciences Stock Price, News & Catalysts
- Ticker:
- REVB
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
0.80 USD (-1.96%)
Close
Last updated: October 1, 2026
4.14M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, REVB closed down 1.96% at $0.8010. No new same-company headline was identified in the current news window.
Company overview
Innate Immune Modulation Company
Revelation Biosciences develops therapies intended to rebalance inflammation in acute and chronic disease. Its lead formulation activates Toll-like receptor 4 to produce a controlled innate immune response.
Gemini Lead Candidate
Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide. Rather than broadly suppressing immunity, the candidate is designed to precondition and recalibrate the inflammatory response.
Acute Kidney Injury Program
The primary development program targets acute kidney injury associated with cardiac surgery. Revelation is preparing an adaptive pivotal study intended to evaluate prevention or reduction of clinically significant kidney injury.
Clinical and Preclinical Evidence
Gemini has been evaluated in Phase 1 studies and in preclinical models of acute kidney injury, chronic kidney disease, and infection. These data support selection of dose, timing, and endpoints for later-stage development.
Manufacturing Readiness
The company has initiated GMP manufacturing of Gemini and placebo for its planned clinical program. External manufacturers, a renal-focused contract research organization, and scientific advisers support execution.
Future catalysts
- Initiation of the adaptive pivotal Phase 2/3 study of Gemini in acute kidney injury in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Revelation Biosciences (REVB)?
Revelation Biosciences (REVB) most recently closed at 0.80 USD, a -1.96% move versus the previous session.
What is the market cap of Revelation Biosciences (REVB)?
Revelation Biosciences currently has a market capitalization of 4.14M USD on BioPharmSignal.
What does Revelation Biosciences do?
Innate Immune Modulation Company Revelation Biosciences develops therapies intended to rebalance inflammation in acute and chronic disease. Its lead formulation activates Toll-like receptor 4 to produce a controlled innate immune response. Gemini Lead Candidate Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide. Rather than broadly...
On which exchange is REVB stock listed?
Revelation Biosciences (REVB) is associated with NASDAQ, United States, MedTech.
What is Innate?
Innate Immune Modulation Company Revelation Biosciences develops therapies intended to rebalance inflammation in acute and chronic disease.
Which conditions is Revelation Biosciences targeting with Innate?
Revelation Biosciences is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Revelation Biosciences describe recent progress with Innate?
Initiation of the adaptive pivotal Phase 2/3 study of Gemini in acute kidney injury in the fourth quarter of 2026.
What is Immune?
Innate Immune Modulation Company Revelation Biosciences develops therapies intended to rebalance inflammation in acute and chronic disease.